INS and type 1 diabetes mellitus: CIPII has clear advantages over SC insulin administration in term of pharmacokinetic and pharmacodynamics properties and has been shown to improve glycemic regulation in T1D patients who failed to reach an adequate glycemic control despite intensive SC insulin therapy.